Literature DB >> 18420285

Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.

Luciane P Gaspar1, Ygara S Mendes, Anna M Y Yamamura, Luiz F C Almeida, Elena Caride, Rafael B Gonçalves, Jerson L Silva, Andréa C Oliveira, Ricardo Galler, Marcos S Freire.   

Abstract

The successful Yellow Fever (YF) vaccine consists of the live attenuated 17D-204 or 17DD viruses. Despite its excellent record of efficacy and safety, serious adverse events have been recorded and influenced extensive vaccination in endemic areas. Therefore, alternative strategies should be considered, which may include inactivated whole virus. High hydrostatic pressure has been described as a method for viral inactivation and vaccine development. The present study evaluated whether high hydrostatic pressure would inactivate the YF 17DD virus. YF 17DD virus was grown in Vero cells in roller bottle cultures and subjected to 310MPa for 3h at 4 degrees C. This treatment abolished YF infectivity and eliminated the ability of the virus to cause disease in mice. Pressure-inactivated virus elicited low level of neutralizing antibody titers although exhibited complete protection against an otherwise lethal challenge with 17DD virus in the murine model. The data warrant further development of pressure-inactivated vaccine against YF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18420285     DOI: 10.1016/j.jviromet.2008.03.002

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  17 in total

1.  Pressure and temperature stability of the main apple allergen Mal d1.

Authors:  Judit Somkuti; Milan Houska; László Smeller
Journal:  Eur Biophys J       Date:  2010-10-15       Impact factor: 1.733

2.  Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice.

Authors:  Kanakatte Raviprakash; Peifang Sun; Yossef Raviv; Thomas Luke; Nicholas Martin; Tadeusz Kochel
Journal:  Hum Vaccin Immunother       Date:  2013-07-08       Impact factor: 3.452

Review 3.  Advances and controversies in yellow fever vaccination.

Authors:  Emile F F Jonker; Leonardus G Visser; Anna H Roukens
Journal:  Ther Adv Vaccines       Date:  2013-11

Review 4.  Molecular dynamics of thermoenzymes at high temperature and pressure: a review.

Authors:  Roghayeh Abedi Karjiban; Wui Zhuan Lim; Mahiran Basri; Mohd Basyaruddin Abdul Rahman
Journal:  Protein J       Date:  2014-08       Impact factor: 2.371

Review 5.  Current status and future prospects of yellow fever vaccines.

Authors:  Andrew S Beck; Alan D T Barrett
Journal:  Expert Rev Vaccines       Date:  2015-09-14       Impact factor: 5.217

6.  Balancing the Efficacy and Safety of Vaccines in the Elderly.

Authors:  Ian J Amanna
Journal:  Open Longev Sci       Date:  2012-06-29

Review 7.  Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?

Authors:  Maria Vadalà; Dimitri Poddighe; Carmen Laurino; Beniamino Palmieri
Journal:  EPMA J       Date:  2017-07-20       Impact factor: 6.543

Review 8.  Questions regarding the safety and duration of immunity following live yellow fever vaccination.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2016-06-20       Impact factor: 5.683

9.  Intranasal Immunization with Pressure Inactivated Avian Influenza Elicits Cellular and Humoral Responses in Mice.

Authors:  Shana P C Barroso; Dirlei Nico; Danielle Nascimento; Ana Clara V Santos; José Nelson S S Couceiro; Fernando A Bozza; Ana M A Ferreira; Davis F Ferreira; Clarisa B Palatnik-de-Sousa; Thiago Moreno L Souza; Andre M O Gomes; Jerson L Silva; Andréa C Oliveira
Journal:  PLoS One       Date:  2015-06-09       Impact factor: 3.240

10.  Potency under pressure: the impact of hydrostatic pressure on antigenic properties of influenza virus hemagglutinin.

Authors:  Schafer L Eichelberger; Ishrat Sultana; Jin Gao; Melkamu Getie-Kebtie; Michail Alterman; Maryna C Eichelberger
Journal:  Influenza Other Respir Viruses       Date:  2013-03-17       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.